Anti-ILF3 Antibody
Specifications
| Product Cat#: | AB-06-2443 |
| Product type: | Primary antibody |
| Antigen: | ILF3 |
| Immunogen: | Recombinant protein of N-terminal human ILF3. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:800-1:2000); Immunoprecipitation(1:10-1:80); Immunocytochemistry (1:80-1:200); Immunofluorescence; Immunohistochemistry (1:80-1:200); Flow Cytometry (1:50-1:200) |
| Reactivity: | Mouse, Rat and Human |
| Clonality (clone number): | Monoclonal(JG37-63) |
| Form: | Liquid |
| Buffer: | 1*TBS (pH 7.4), 1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | CBTF antibody |
| Double stranded RNA binding protein 76 antibody | |
| Double-stranded RNA-binding protein 76 antibody | |
| DRBF antibody | |
| DRBP76 antibody | |
| ILF3 antibody | |
| ILF3_HUMAN antibody | |
| Interleukin enhancer binding factor 3 antibody | |
| Interleukin enhancer-binding factor 3 antibody | |
| M phase phosphoprotein 4 antibody | |
| M-phase phosphoprotein 4 antibody | |
| MPHOSPH4 antibody | |
| MPP4 antibody | |
| NF AT 90 antibody | |
| NF-AT-90 antibody | |
| NF110 antibody | |
| NF90 antibody | |
| NFAR antibody | |
| Nuclear factor associated with dsRNA antibody | |
| Nuclear factor of activated T cells 90 kDa antibody | |
| Nuclear factor of activated T-cells 90 kDa antibody | |
| TCP80 antibody | |
| Translational control protein 80 antibody |
Target information
RNA-binding protein that plays an essential role in the biogenesis of circular RNAs (circRNAs) which are produced by back-splicing circularization of pre-mRNAs. Within the nucleus, promotes circRNAs processing by stabilizing the regulatory elements residing in the flanking introns of the circularized exons. Plays thereby a role in the back-splicing of a subset of circRNAs (PubMed:28625552). As a consequence, participates in a wide range of transcriptional and post-transcriptional processes. Binds to poly-U elements and AU-rich elements (AREs) in the 3′-UTR of target mRNAs (PubMed:14731398). Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response (PubMed:21123651). Mechanistically, ILF3 becomes phosphorylated and activated by the double-stranded RNA-activated protein kinase/PKR which releases ILF3 from cellular mature circRNAs. In turn, unbound ILF3 molecules are able to interact with and thus inhibit viral mRNAs (PubMed:21123651, PubMed:28625552).
Provider
Erpantech Laboratory
